(AOF) – Nanobiotix has obtained an agreement in principle from the European Investment Bank to restructure 30.7 million euros from the loan agreement signed in 2018. The agreement in principle is structured around cash flows expected by Nanobiotix around its potential future growth levers, including the hypothesis of the commercialization of NBTXR3 and possible partnerships.
This agreement initially provides for the deferral of approximately 25.3 million euros of capital repayment until June 2029 and of approximately 5.4 million euros of capitalized interest payments until October 2024.
It also includes the payment in 2029 of an additional amount limited to a maximum of 20 million euros, the maturity of which could be accelerated if one of these expected cash flows occurs.
The original claim will continue to accrue interest payable until the new due dates. The start of the six-year annual royalty period is also postponed to begin on the first commercialization date of NBTXR3.
“The restructuring of this EIB loan by extending its maturity date will allow Nanobiotix to focus on its priority NBTXR3 development programs through 2023 while expanding its operating capacity by a quarter. With the potential access to additional capital resources at Using the existing equity line, the operating company. the capacity could extend until the first quarter of 2024, “said art Van Rhijn, financial director of Nanobiotix.
AOF – LEARN MORE
An inevitable rush for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, from 2019, of the patents for its three-star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent lasts only ten to fifteen years. This leads laboratories to withdraw from certain activities. So J&J, Pfizer, GSK and, no doubt, Novartis will soon be quick to refocus on specialty drugs and abandon any ancillary activities.